Publications

5491 Results

INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer. Toxicity update on first 73 patients

Authors
P Singh;J Efstathiou;C Tangen;S Jhavar;N Hahn;B Costello;S Delacroix;A Tripathi;Sachdev;J Gills;A Jani;R Bangs;M Plets;N Vogelzang;IM Thompson;F Feng;SP Lerner
Journal / Conference
J Clin Oncol 39, 2021 (suppl 6; abstr 428) (ASCO GU Cancers Symposium (Feb 13-15, 2021 virtual), poster)
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S1806

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605 (NCT #02844816)

Authors
P Black;C Tangen;P Singh;D McConkey;MS Lucia;W Lowrance;V Koshkin;K Stratton;T Bivalacqua;W Kassouf;S Porten;R Bangs;SP Lerner;I Thompson, Jr.
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 4541) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S1605

Body Composition Measurements and Overall Survival in Patients with Resectable Pancreatic Adenocarcinoma (SWOG Study S1505)

Authors
D Sohal;M Duong;R Boutin;L Lenchik;J Kim;N Gandhi;MS Beg;A Wang-Gillam;JL Wade;K Guthrie;EG Chiorean;S Ahmad;A Lowy;H Hochster;PA Philip;V Chang
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 4131) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

Does Adjuvant Chemoradiation Benefit Patients with Lymph Node Positive Biliary Tract Cancers? : A Secondary Analysis of SWOG S0809

Authors
S Gholami;M Duong;D Horowitz;K Guthrie;E Ben-Josef;A El-Khoueiry;CD Blanke;PA Philip;L Kachnic;S Ahmad;F Rocha
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 4104) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
S0809

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer—toxicity update (Lung-MAP non-matched sub-study S1800A)

Authors
K Reckamp;M Redman;K Dragnev;L Villaruz;B Faller;T Al Baghdadi;S Hines;L Qian;K Minichiello;DR Gandara;RS Herbst;K Kelly
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 9075) (American Society of Clinical Oncology Annual Meeting 2021, poster session)
Year
2021
Research Committee(s)
Lung
Study Number(s)
S1800A

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll): Evolve Cll/Sll Study (SWOG S1925; NCT#04269902)

Authors
D Stephens;A Moseley;B Hill;J Pagel;M Shadman;M Fisch;A Danilov;D Ng;A Mato;D Brander;M Othus;S Coutre;S O'Brien;H Erba
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7567) (American Society of Clinical Oncology Annual Meeting 2021 (TIPS), poster session)
Year
2021
Research Committee(s)
Leukemia
Study Number(s)
S1925

A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV Non-Small Cell Lung Cancer (Lung-Map Sub-Study): SWOG S1900A

Authors
J Riess;M Redman;P Wheatley-Price;B Faller;L Villaruz;L Corum;A Gowda;G Srkalovic;R Osarogiabon;M Baumgart;L Qian;K Minichiello;DR Gandara;RS Herbst;K Kelly
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 9024) (American Society of Clinical Oncology Annual Meeting 2021, poster discussion session)
Year
2021
Research Committee(s)
Lung
Study Number(s)
S1900A

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691)

Authors
N Agarwal;C Tangen;MHA Hussain;S Gupta;M Plets;P Lara;A Harzstark;P Twardowski;C Paller;D Zylla;M Zibelman;E Levine;B Roth;A Goldkorn;D Vaena;M Kohli;A Crispino;N Vogelzang;IM Thompson;DI Quinn
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 5001) (American Society of Clinical Oncology Annual Meeting 2021, oral)
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Final Analysis of Overall Survival (OS) and Relapse-Free-Survival (RFS) in the Intergroup S1404 Phase III Randomized Trial Comparing Either High Dose Interferon (HDI) or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

Authors
K Grossmann;M Othus;S Patel;A Tarhini;V Sondak;T Petrella;T-G Truong;N Khushalani;JV Cohen;E Buchbinder;K Kendra;P Funchain;K Lewis;B Chmielowski;H Li;J Moon;K Gunturu;Z Eroglu;JM Kirkwood;A Ribas
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 9501) (American Society of Clinical Oncology Annual Meeting 2021, oral)
Year
2021
Research Committee(s)
Melanoma
Study Number(s)
S1404

E1411 Randomized Phase 2 Trial of Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma: Addition of Bortezomib to Front-Line BR Induction does not prolong PFS

Authors
MR Smith;O Jegede;P Martin;B Till;S Parekh;D Yang;L Kostakoglu Shields;C Casulo;N Bartlett;P Caimi;T Al Baghdadi;K Maddocks;M Romer;D Inwards;R Lerner;L Wagner;R Little;J Friedberg;J Leonard;B Kahl
Journal / Conference
J Clin Oncol 39, 2021 (suppl 15; abstr 7503) (American Society of Clinical Oncology Annual Meeting 2021, oral)
Year
2021
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/E1411